Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab

American Journal of Ophthalmology

Volumn 153, Issue 2, 2012, Pages

  Ma, Yan ^a   Zhang, Yan ^a   Zhao, Tong ^a   Jiang, Yan Rong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; ARTICLE; COMPARATIVE STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VITREOUS BODY;

EID: 84856006425     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.08.006     Document Type: Article

References (22)

1. S.E. Moss, R. Klein, B.E. Klein The 14-year incidence of visual loss in a diabetic population Ophthalmology 105 6 1998 998 1003 (Pubitemid 28268322)
2. L.P. Aiello, R.L. Avery, P.G. Arrigg et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 22 1994 1480 1487 (Pubitemid 24356306)
3. N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol 280 6 2001 C1358 C1366 (Pubitemid 32553190)
4. N.M. Pandya, N.S. Dhalla, D.D. Santani Angiogenesisa new target for future therapy Vascul Pharmacol 44 5 2006 265 274
5. R. Sim, E. Carrasco, M. Garca-Ramrez, C. Hernndez Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy Curr Diabetes Rev 2 1 2006 71 98 (Pubitemid 44082952)
6. The Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8 Ophthalmology 88 7 1981 583 600
7. K. Shinoda, S. Ishida, S. Kawashima et al. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy Curr Eye Res 21 2 2000 655 661
8. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1971 1182 1186
9. J.B. Gunther, M.M. Altaweel Bevacizumab (Avastin) for the treatment of ocular disease Surv Ophthalmol 54 3 2009 372 400
10. N. Arimura, H. Otsuka, K. Yamakiri et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy Ophthalmology 116 5 2009 921 926
11. J. Qian, Q. Lu, Y. Tao, Y.R. Jiang Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy Retina 31 1 2011 161 168
12. R.L. Avery, J. Pearlman, D.J. Pieramici et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 10 2006 1695 e1e15
13. Y. Jiang, X. Liang, X. Li, Y. Tao, K. Wang Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy Acta Ophthalmol 87 7 2009 736 740
14. J.O. Mason 3rd, P.A. Nixon, M.F. White Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy Am J Ophthalmol 142 4 2006 685 688 (Pubitemid 44442055)
15. D. Watanabe, K. Suzuma, I. Suzuma et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy Am J Ophthalmol 139 3 2005 476 481 (Pubitemid 40379074)
16. L.P. Aiello, E.A. Pierce, E.D. Foley et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 23 1995 10457 10461
17. J.W. Miller, A.P. Adamis, D.T. Shima et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145 3 1994 574 584 (Pubitemid 24285965)
18. E.A. Pierce, R.L. Avery, E.D. Foley, L.P. Aiello, L.E. Smith Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization Proc Natl Acad Sci U S A 92 3 1995 905 909
19. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, R.J. Singh Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 5 2007 855 859 (Pubitemid 46635858)
20. X. Wang, G. Wang, Y. Wang Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy Am J Opthalmol 148 6 2009 883 889
21. H. Funatsu, H. Yamashita, Y. Nakanishi, S. Hori Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy Br J Ophthalmol 86 3 2002 311 315 (Pubitemid 34206346)
22. R.L. Avery Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment Retina 26 3 2006 352 354 (Pubitemid 44318195)